Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors
N/A
N/A
Both
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Trial Information
Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors
OBJECTIVES:
I. Determine the maximum tolerated dose of BMS-214662 in patients with solid tumors.
II. Evaluate intermediate biological endpoints as surrogates for the effectiveness of this
drug in these patients.
III. Determine the nature of dose limiting toxicity of this drug in this patient population.
IV. Determine the recommended phase II regimen of this drug in these patients. V. Establish
a pharmacologic and pharmacokinetic profile of this drug in these patients.
OUTLINE: This is a dose escalation study.
Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every
6 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience
dose limiting toxicities.
Patients are followed every 3 months for at least 24 months.
Inclusion Criteria:
- Diagnosis of malignant solid tumor for which a standard curative therapy does not
exist
- Performance status - Karnofsky 70-100%
- At least 6 months
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10.0 g/dL
- Bilirubin no greater than 2.0 mg/dL
- AST no greater than 2 times upper limit of normal
- Albumin at least 3.0 g/dL
- Creatinine no greater than 1.5 mg/dL
- No uncontrolled heart disease
- No history of clinically significant cardiac arrhythmia that could be exacerbated by
QT interval prolongation
- Corrected QT interval no greater than 450 milliseconds
- Must not require total parenteral nutrition
- No manifestations of malabsorption syndrome due to prior surgery, gastrointestinal
disease, or unknown reasons
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No signs or symptoms of acute infection requiring systemic therapy
- No grade 3 or 4 neurotoxicity from prior anticancer treatment or neuropathy from any
cause
- No confusion, disorientation, or psychiatric illness that may preclude study
- No more than 3 prior chemotherapy regimens
- At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or
mitomycin) and recovered
- No other concurrent antineoplastic agents
- No concurrent hormonal anticancer therapy
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy
- Prior drugs known to prolong the QT interval allowed if they can be safely
discontinued for a time period equal to 4 elimination half-lives prior to
administering study drug
- No drugs known to prolong the QT interval during and for 24 hours after study drug
- No concurrent therapy with known CYP3A4 substrates
- No other concurrent investigational agents
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
MTD, defined as the dose level among the 9 levels studied having toxicity rate closest to a target of 33%, graded according to CTC version 2.0
Outcome Description:
Toxicity is defined as grade 3, 4 non-hematologic and grade 4 hematologic (neutropenia and thrombocytopenia) toxicity. The continual reassessment method (CRM) will be used.
Outcome Time Frame:
Up to 6 weeks
Safety Issue:
Yes
Principal Investigator
Vassiliki Papadimitrakopoulou
Investigator Role:
Principal Investigator
Investigator Affiliation:
M.D. Anderson Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
NCI-2012-02343
NCT ID:
NCT00005973
Start Date:
April 2000
Completion Date:
Related Keywords:
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific
- Neoplasms
Name | Location |
|---|---|
| M D Anderson Cancer Center | Houston, Texas 77030 |
